OPKO Health Files 8-K on Security Holder Vote
Ticker: OPK · Form: 8-K · Filed: Mar 29, 2024 · CIK: 944809
| Field | Detail |
|---|---|
| Company | Opko Health, INC. (OPK) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: OPK
TL;DR
OPKO Health shareholders voted on something important, details TBD.
AI Summary
On March 28, 2024, OPKO Health, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not disclose specific details about the proposals voted on or the outcome of the vote.
Why It Matters
This filing signals that important corporate decisions were put to a vote by OPKO Health's shareholders, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain new financial information or significant operational changes.
Key Players & Entities
- OPKO Health, Inc. (company) — Registrant
- March 28, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted for a vote by OPKO Health's security holders?
The 8-K filing does not specify the exact matters that were submitted for a vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 28, 2024.
What is the principal executive office address for OPKO Health, Inc.?
The principal executive offices are located at 4400 Biscayne Blvd., Miami, Florida 33137.
What is the IRS Employer Identification Number for OPKO Health, Inc.?
The IRS Employer Identification Number is 75-2402409.
What is the SIC code for OPKO Health, Inc.?
The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Stats: 695 words · 3 min read · ~2 pages · Grade level 7.8 · Accepted 2024-03-29 16:05:39
Key Financial Figures
- $0.01 — ch registered Common Stock , par value $0.01 per share OPK NASDAQ Global Select M
Filing Documents
- opk20240220c_8k.htm (8-K) — 64KB
- 0001437749-24-010069.txt ( ) — 195KB
- opk-20240328.xsd (EX-101.SCH) — 3KB
- opk-20240328_def.xml (EX-101.DEF) — 11KB
- opk-20240328_lab.xml (EX-101.LAB) — 15KB
- opk-20240328_pre.xml (EX-101.PRE) — 11KB
- opk20240220c_8k_htm.xml (XML) — 3KB
07
ITEM 5.07. Submission of Matters to a Vote of Security Holders. On March 28, 2024, OPKO Health, Inc., (the "Company") held its 2024 Annual Meeting of Stockholders (the " Annual Meeting "). Below is a summary of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting and the corresponding votes. 1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows: Election of Directors For Against Abstain Broker Non-Votes Phillip Frost, M.D. 417,952,041 22,474,563 6,171,466 84,699,761 Jane H. Hsiao, Ph.D. 413,880,317 26,420,093 6,297,660 84,699,761 Elias A. Zerhouni, M.D. 414,360,287 26,147,182 6,090,601 84,699,761 Steven D. Rubin 409,265,433 31,259,959 6,072,678 84,699,761 Gary J. Nabel, M.D., Ph.D. 414,266,144 26,217,873 6,114,053 84,699,761 Richard M. Krasno, Ph.D. 433,053,909 12,897,229 646,932 84,699,761 Prem A. Lachman, M.D. 435,390,598 10,489,096 718,376 84,699,761 Roger J. Medel, M.D. 435,237,621 10,618,192 742,257 84,699,761 John A. Paganelli 415,788,107 29,404,640 1,405,323 84,699,761 Richard C. Pfenniger, Jr. 419,052,214 26,216,424 1,329,432 84,699,761 Alice Lin-Tsing Yu, M.D., Ph.D. 438,269,264 7,742,819 585,987 84,699,761 2. The stockholders voted to approve an amendment to the Company's amended and restated certificate of incorporation to increase the authorized number of shares of the Company's Common Stock that the Company may issue from 1,000,000,000 shares to 1,250,000,000 shares as disclosed in the 2024 Proxy Statement for the Annual Meeting. The votes on the OPKO authorized share increase proposal were as follows: For Against Abstain 492,393,778 37,918,739 985,314 3. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company's 2024 Proxy Statement for the Annual Meeting. The votes on this pro
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Steven D. Rubin Date: March 29, 2024 Name: Steven D. Rubin Title: Executive Vice President-Administration